and no less.
upgrades keep coming..nice.
company has other drugs on the market also : )
no brainer--long here
Even higher if you look at EPS estimates for 2016 of 6.25. Use a 40x multiple and you are talking about a $250 say by mid-2015. This should be a core biotech holding over the next 5+ years.